We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00601146
Recruitment Status : Active, not recruiting
First Posted : January 25, 2008
Results First Posted : February 17, 2016
Last Update Posted : August 24, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
This research study is being done because patients with a history of chest radiation treatment for Hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment. The risk appears to be further increased among patients with a smoking history. Currently, the practice is to recommend annual low-dose chest CT scans in survivors of Hodgkin's disease who have received prior chest radiation treatment and who have at least a moderate smoking history. In this study, the CT scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner.

Condition or disease Intervention/treatment
Lung Cancer Procedure: chest computed tomography scan

Detailed Description:
- Participants will undergo a chest computed tomography (CT) scan once a year for a 3-year period.

Study Design

Study Type : Observational
Actual Enrollment : 39 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease
Study Start Date : November 2006
Primary Completion Date : December 2010
Estimated Study Completion Date : December 2018

Groups and Cohorts

Intervention Details:
    Procedure: chest computed tomography scan
    Once a year for three years
    Other Name: CT scan

Outcome Measures

Primary Outcome Measures :
  1. To Prospectively Collect Data on Chest CT Screening for Patients at Increase Lung-cancer Risk After Hodgkin's Disease. [ Time Frame: 3 years ]
    In this study, patients will under annual low-dose chest CT screening. The total number of lung cancer detected through the screening will be recorded

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Survivors of Hodgkin's disease seen for follow-up at the Brigham and Women's Hosptial Department of Radiation Oncology, the Lance Armstrong Adult Survivorship Clinic and the David B. Perini Jr. Childhood Cancer Survivor Clinic at the Dana Farber-Cancer Institute

Inclusion Criteria:

  • 5 years or longer from initial Hodgkin's disease diagnosis
  • Current age 18 or older
  • Received mediastinal irradiation and/or alkylating-agent based chemotherapy
  • Smoking history of 10-pack years or more, or current smoker
  • Pre-approval from the participant's insurance company for the CT study

Exclusion Criteria:

  • Patients with a history of lung cancer
  • Currently receiving treatment for another cancer diagnosis
  • Known diagnosis of any metastatic cancer
  • Pregnant women
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00601146

United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Principal Investigator: Andrea K. Ng, MD Dana-Farber Cancer Institute/Brigham and Women's Hospital
More Information

Responsible Party: Andrea K. Ng, MD, Radiation Oncologist, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT00601146     History of Changes
Other Study ID Numbers: 06-122
First Posted: January 25, 2008    Key Record Dates
Results First Posted: February 17, 2016
Last Update Posted: August 24, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Andrea K. Ng, MD, Dana-Farber Cancer Institute:
Hodgkin's disease
CT scan

Additional relevant MeSH terms:
Hodgkin Disease
Lung Diseases
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type